.jpeg)
{{ variable.name }}
Tenofovir alafenamide Fumarate) is a new nucleotide reverse transcriptase inhibitor mainly used to treat chronic hepatitis B (CHB) in adults and adolescents (age 12 years and above, weighing at least 35kg).
Trade name: Vemlidy
Common name: Tenofovir alafenamide tablets
English name: T enofovirAlafenamide Tablets
Vemlidy is suitable for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensatory liver disease.
Specifications: Each tablet contains 25 mg of tenofovir alafenamide fumarate (based on tenofovir alafenamide, it is equivalent to 28 mg of tenofovir alafenamide fumarate).
Characteristics: Yellow round film-coated tablet, engraved with "GSI" on one side and "25" on the other side.
Active ingredient:TenofovirAlafenamide
Excipients: Including croscarmellose sodium, lactose monohydrate, magnesium stearate and microcrystalline cellulose, etc. The film coating material contains yellow iron oxide, polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
Recommended dosage: Adults take 25 mg (one tablet) once a day, orally with food.
Patients with renal insufficiency: Patients with mild, moderate or severe renal insufficiency do not need to adjust the dose.
However, it is not recommended for patients with end-stage renal disease (estimated creatinine clearance less than 15mL/min).
Patients with hepatic impairment: No dose adjustment is required for patients with mild hepatic impairment (Child-Pugh Class A).
However, it is not recommended for patients with decompensated (Child-Pugh B or C) liver disease.
Before and after meals: It should be taken with food to increase the bioavailability of the drug.
Missed dose: If you miss a dose, you should take it as soon as possible, unless it is close to the time of the next dose, in which case you should skip the missed dose and continue taking it at the normal dose.
Vomiting: If you vomit within 1 hour after taking the medicine, you should take another tablet; if it exceeds 1 hour, there is no need to take a supplement and continue taking the next medicine at the normal time.
Pregnant and lactating women: Pregnant women have limited medication data, and the pros and cons should be weighed before use; lactating women should suspend breastfeeding while taking the medication.
Children: Safety and effectiveness have not been established in children under 18 years of age.
Older adults: Clinical studies did not include sufficient numbers of older adults aged 65 and older to determine whether they respond differently than younger adults.
Common adverse reactions (incidence ≥5%):Headache, abdominal pain, fatigue, cough, nausea, and back pain.
Serious adverse reactions:Including lactic acidosis/severe hepatomegaly with steatosis, severe acute exacerbation of hepatitis B after treatment, new or worsening renal insufficiency, etc.
It is prohibited for those allergic to Vemlidy or any excipients.
Vemlidy is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Drugs that strongly affect the activity of P-gp and BCRP may change the absorption of Vemlidy.
Avoid coadministration with potent P-gp inducers (such as carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampicin, rifapentine, St. John's wort), as the plasma concentration of Vemlidy may be significantly reduced.
Store below 30°C (86°F), keep containers tightly closed, and only use original containers for distribution.